Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.

Jung Hee KimDong Hyun SinnWonseok KangGeum-Youn GwakYong-Han PaikMoon Seok ChoiJoon Hyeok LeeKwang Cheol KohSeung Woon Paik

Published in: Hepatology (Baltimore, Md.) (2016)

LLV observed during entecavir monotherapy was associated with a higher risk of HCC, especially for those with cirrhosis, indicating that LLV during potent antiviral therapy is consequential. (Hepatology 2017;66:335-343).

Keyphrases

combination therapy
open label
randomized controlled trial
clinical trial
anti inflammatory
bone marrow
study protocol